Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD). The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV being developed for the prevention of IPD in adults and children. VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI to prevent dysentery and shigellosis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Period	fcf
2020-12-31	-$47.73M
2021-12-31	-$127.95M
2022-12-31	-$176.44M
2023-12-31	-$364.67M
2024-12-31	-$571.79M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PCVX	$60.69	-0.01%	0.79M
3
4
5

Vaxcyte Inc. (PCVX) Free Cash Flow

Free Cash Flow Data

Get Vaxcyte Inc. Data in Excel

More PCVX Financial Data